195 related articles for article (PubMed ID: 27709415)
1. Pathology of Human Pheochromocytoma and Paraganglioma Xenografts in NSG Mice.
Powers JF; Pacak K; Tischler AS
Endocr Pathol; 2017 Mar; 28(1):2-6. PubMed ID: 27709415
[TBL] [Abstract][Full Text] [Related]
2. Clinical risk factors for malignancy and overall survival in patients with pheochromocytomas and sympathetic paragangliomas: primary tumor size and primary tumor location as prognostic indicators.
Ayala-Ramirez M; Feng L; Johnson MM; Ejaz S; Habra MA; Rich T; Busaidy N; Cote GJ; Perrier N; Phan A; Patel S; Waguespack S; Jimenez C
J Clin Endocrinol Metab; 2011 Mar; 96(3):717-25. PubMed ID: 21190975
[TBL] [Abstract][Full Text] [Related]
3. Comparison of pheochromocytomas and abdominal and pelvic paragangliomas with head and neck paragangliomas.
Al-Harthy M; Al-Harthy S; Al-Otieschan A; Velagapudi S; Alzahrani AS
Endocr Pract; 2009 Apr; 15(3):194-202. PubMed ID: 19364686
[TBL] [Abstract][Full Text] [Related]
4. Cytocidal activities of topoisomerase 1 inhibitors and 5-azacytidine against pheochromocytoma/paraganglioma cells in primary human tumor cultures and mouse cell lines.
Powers JF; Korgaonkar PG; Fliedner S; Giubellino A; Pacak K; Sahagian GG; Tischler AS
PLoS One; 2014; 9(2):e87807. PubMed ID: 24516563
[TBL] [Abstract][Full Text] [Related]
5. N-Glycomic Profiling of Pheochromocytomas and Paragangliomas Separates Metastatic and Nonmetastatic Disease.
Leijon H; Kaprio T; Heiskanen A; Satomaa T; Hiltunen JO; Miettinen MM; Arola J; Haglund C
J Clin Endocrinol Metab; 2017 Nov; 102(11):3990-4000. PubMed ID: 28938401
[TBL] [Abstract][Full Text] [Related]
6. Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra-adrenal and metastatic tumors.
Babic B; Patel D; Aufforth R; Assadipour Y; Sadowski SM; Quezado M; Nilubol N; Prodanov T; Pacak K; Kebebew E
Surgery; 2017 Jan; 161(1):220-227. PubMed ID: 27865588
[TBL] [Abstract][Full Text] [Related]
7. [Tumors of the adrenal medulla and the paraganglia].
Klöppel G
Pathologe; 2003 Jul; 24(4):280-6. PubMed ID: 14513275
[TBL] [Abstract][Full Text] [Related]
8. Histopathology, cytology and cytochemistry of pheochromocytomas and paragangliomas including chemodectomas.
Capella C; Riva C; Cornaggia M; Chiaravalli AM; Frigerio B; Solcia E
Pathol Res Pract; 1988 Apr; 183(2):176-87. PubMed ID: 2838831
[TBL] [Abstract][Full Text] [Related]
9. Pathology of pheochromocytoma and extra-adrenal paraganglioma.
Tischler AS; Kimura N; Mcnicol AM
Ann N Y Acad Sci; 2006 Aug; 1073():557-70. PubMed ID: 17102124
[TBL] [Abstract][Full Text] [Related]
10. [Pheochromocytoma and sympathetic paragangliomas].
Zollinger R; Hedinger C
Schweiz Med Wochenschr; 1983 Jul; 113(30):1057-65. PubMed ID: 6623024
[TBL] [Abstract][Full Text] [Related]
11. Pheochromocytomas and Paragangliomas: An Update on Recent Molecular Genetic Advances and Criteria for Malignancy.
Guo Z; Lloyd RV
Adv Anat Pathol; 2015 Sep; 22(5):283-93. PubMed ID: 26262510
[TBL] [Abstract][Full Text] [Related]
12. KI-67 AND hTERT expression can aid in the distinction between malignant and benign pheochromocytoma and paraganglioma.
Elder EE; Xu D; Höög A; Enberg U; Hou M; Pisa P; Gruber A; Larsson C; Bäckdahl M
Mod Pathol; 2003 Mar; 16(3):246-55. PubMed ID: 12640105
[TBL] [Abstract][Full Text] [Related]
13. Pheochromocytomas and paragangliomas in humans and dogs.
Galac S; Korpershoek E
Vet Comp Oncol; 2017 Dec; 15(4):1158-1170. PubMed ID: 28120550
[TBL] [Abstract][Full Text] [Related]
14. DNA flow cytometry in pheochromocytoma and paraganglioma.
Jung WH; Yang WI; Park C; Choi IJ
Yonsei Med J; 1992 Sep; 33(3):249-57. PubMed ID: 1292249
[TBL] [Abstract][Full Text] [Related]
15. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
16. Nonsporadic cases and unusual morphological features in pheochromocytoma and paraganglioma.
Lamovec J; Frković-Grazio S; Bracko M
Arch Pathol Lab Med; 1998 Jan; 122(1):63-8. PubMed ID: 9448019
[TBL] [Abstract][Full Text] [Related]
17. Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumors.
Sadow PM; Rumilla KM; Erickson LA; Lloyd RV
Endocr Pathol; 2008; 19(2):97-103. PubMed ID: 18461287
[TBL] [Abstract][Full Text] [Related]
18. Immunohistochemical localization of endothelin-1, endothelin-3 and endothelin receptors in human pheochromocytoma and paraganglioma.
Watanabe K; Hiraki H; Hasegawa H; Tanigawa T; Emura I; Honma K; Shibuya H; Fukuda T; Suzuki T
Pathol Int; 1997 Aug; 47(8):540-6. PubMed ID: 9293534
[TBL] [Abstract][Full Text] [Related]
19. MANAGEMENT OF ENDOCRINE DISEASE: Recurrence or new tumors after complete resection of pheochromocytomas and paragangliomas: a systematic review and meta-analysis.
Amar L; Lussey-Lepoutre C; Lenders JW; Djadi-Prat J; Plouin PF; Steichen O
Eur J Endocrinol; 2016 Oct; 175(4):R135-45. PubMed ID: 27080352
[TBL] [Abstract][Full Text] [Related]
20. COPPS, a composite score integrating pathological features, PS100 and SDHB losses, predicts the risk of metastasis and progression-free survival in pheochromocytomas/paragangliomas.
Pierre C; Agopiantz M; Brunaud L; Battaglia-Hsu SF; Max A; Pouget C; Nomine C; Lomazzi S; Vignaud JM; Weryha G; Oussalah A; Gauchotte G; Busby-Venner H
Virchows Arch; 2019 Jun; 474(6):721-734. PubMed ID: 30868297
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
